189 related articles for article (PubMed ID: 11105535)
21. Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection.
Bodhe PV; Kotwani RN; Kirodian BG; Kshirsagar NA; Pandya SK
J Assoc Physicians India; 2002 May; 50(5):662-70. PubMed ID: 12186120
[TBL] [Abstract][Full Text] [Related]
22. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
23. Voriconazole versus amphotericin B in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Johansen HK
Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
[TBL] [Abstract][Full Text] [Related]
24. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
25. Liposomal amphotericin B for the treatment of severe fungal infection.
Michaud D
Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
[TBL] [Abstract][Full Text] [Related]
26. Conventional vs. liposomal amphotericin B in immunosuppressed children.
Zoubek A; Emminger W; Emminger-Schmidmeier W; Peters C; Pracher E; Grois N; Gadner H
Pediatr Hematol Oncol; 1992; 9(2):187-90. PubMed ID: 1524992
[TBL] [Abstract][Full Text] [Related]
27. [Meta-analysis on safety and efficacy of liposomal amphotericin B in the empirical treatment of febrile neutropenia].
Badia X; Roset M; Carreras E; Ausin I; Herrera L
Med Clin (Barc); 2004 May; 122(16):610-6. PubMed ID: 15142508
[TBL] [Abstract][Full Text] [Related]
28. Low-dose amphotericin B lipid complex for the treatment of persistent fever of unknown origin in patients with hematologic malignancies and prolonged neutropenia.
Martino R; Subirá M; Domingo-Albós A; Sureda A; Brunet S; Sierra J
Chemotherapy; 1999; 45(3):205-12. PubMed ID: 10224343
[TBL] [Abstract][Full Text] [Related]
29. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
Cannon JP; Garey KW; Danziger LH
Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
[TBL] [Abstract][Full Text] [Related]
30. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.
Kelsey SM; Goldman JM; McCann S; Newland AC; Scarffe JH; Oppenheim BA; Mufti GJ
Bone Marrow Transplant; 1999 Jan; 23(2):163-8. PubMed ID: 10197802
[TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
Stam WB; Aversa F; Kumar RN; Jansen JP
Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
[TBL] [Abstract][Full Text] [Related]
32. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
Wolff SN; Fay J; Stevens D; Herzig RH; Pohlman B; Bolwell B; Lynch J; Ericson S; Freytes CO; LeMaistre F; Collins R; Pineiro L; Greer J; Stein R; Goodman SA; Dummer S
Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206
[TBL] [Abstract][Full Text] [Related]
33. Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients.
Böhme A; Hoelzer D
Mycoses; 1996; 39(11-12):419-26. PubMed ID: 9144997
[TBL] [Abstract][Full Text] [Related]
34. Pancreatic toxicity after liposomal amphotericin B.
Stuecklin-Utsch A; Hasan C; Bode U; Fleischhack G
Mycoses; 2002 Jun; 45(5-6):170-3. PubMed ID: 12100534
[TBL] [Abstract][Full Text] [Related]
35. Experience with liposomal Amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation.
Krüger W; Stockschläder M; Rüssmann B; Berger C; Hoffknecht M; Sobottka I; Kohlschütter B; Kroschke G; Kröger N; Horstmann M
Br J Haematol; 1995 Nov; 91(3):684-90. PubMed ID: 8555076
[TBL] [Abstract][Full Text] [Related]
36. AmBisome (liposomal amphotericin B): a comparative review.
Boswell GW; Buell D; Bekersky I
J Clin Pharmacol; 1998 Jul; 38(7):583-92. PubMed ID: 9702842
[TBL] [Abstract][Full Text] [Related]
37. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
[TBL] [Abstract][Full Text] [Related]
38. Liposomal amphotericin B for fever and neutropenia.
Prentice HG; Kibbler CC
N Engl J Med; 1999 Oct; 341(15):1152-3; author reply 1154-5. PubMed ID: 10515751
[No Abstract] [Full Text] [Related]
39. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
Brogden RN; Goa KL; Coukell AJ
Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
[TBL] [Abstract][Full Text] [Related]
40. Overview of the lipid formulations of amphotericin B.
Dupont B
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():31-6. PubMed ID: 11801578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
